Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia

Franck Rapaport, Yaseswini Neelamraju, Timour Baslan, Duane Hassane, Agata Gruszczynska, Marc Robert de Massy, Noushin Farnoud, Samuel Haddox, Tak Lee, Juan Medina-Martinez, Caroline Sheridan, Alexis Thurmond, Michael Becker, Stefan Bekiranov, Martin Carroll, Heardly Moses Murdock, Peter J.M. Valk, Lars Bullinger, Richard D’Andrea, Scott W. LoweDonna Neuberg, Ross L. Levine, Ari Melnick, Francine E. Garrett-Bakelman*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Downloads (Pure)
Original languageEnglish
Pages (from-to)2688-2692
Number of pages5
Issue number9
Publication statusPublished - 12 Feb 2021

Bibliographical note

Funding Information:
Advancing Translational Sciences, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program to FR. Starr Cancer Consortium grant I4-A442 to AMM and RL, LLS SCOR 7006-13 to AMM, NCI UG1 CA2333332 to AMM. Funding from the William C. and Joyce C. O’Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative to TB. NCI grant CA190261 to SWL. The South Australian Cancer Research Biobank (SACRB) is supported by the Cancer Council SA Beat Cancer Project, Medvet Laboratories Pty Ltd and the Government of South Australia. The authors thank the following service providers: Next generation sequencing services were provided by the New York Genome Center and Weill Cornell Medicine Genomics Core facility. Computational resources and technical support were provided by the Weill Cornell Medicine Applied Bioinformatics, the Memorial Sloan Kettering Bioinformatics cores and the School of Medicine Research Computing at The University of Virginia. MRM is currently affiliated with the Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK, TL is currently currently affiliated with Hunter College, and CS is currently affiliated with Immunai.

Funding Information:
Funding NCI K08CA169055, UVA Cancer Center through the NCI Cancer Center Support Grant P30 CA44579, the University of Virginia and funding from the American Society of Hematology (ASHAMFDP-20121) under the ASH-AMFDP partnership with The Robert Wood Johnson Foundation and ASH/EHA TRTH to FGB. Partial support UL1 TR001866 from the National Center for

Cite this